Blanket Purchase Agreement V797D60634-VA797P16A0025

The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Chiasma, Inc. for the procurement of MYCAPSSA. As a single award BPA under the Pharmaceuticals and Drugs GSA Schedule, it provides a contracting vehicle valued at up to $250,000 to order MYCAPSSA, an acromegaly treatment, through October 13, 2022. MYCAPSSA is an octreotide capsule administered orally for the long-term maintenance treatment of acromegaly in adults who have responded...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Corcept Therapeutics Incorporated. The contract has a ceiling value of $3,700,000.00 and an ultimate completion date of September 5, 2024. The purpose of this BPA is to provide the agency with Korlym, a pharmaceutical drug. This BPA was established under the General Services Administration (GSA) Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs. The contract is a single...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

This Blanket Purchase Agreement, awarded on October 4, 2025, by the National Acquisition Center (a civilian federal agency) to Takeda Pharmaceuticals America, Inc., establishes a $43.8 million single-award indefinite delivery vehicle for the supply of ICLUSIG (ponatinib) to Department of Veterans Affairs medical facilities. The contract, which operates as a child contract under the General Services Administration Schedule for Pharmaceuticals and Drugs (FSS-61-IB), enables VA facilities to...

Otsuka America Pharmaceutical Inc. was awarded a single-award Blanket Purchase Agreement (BPA) by the National Acquisition Center with a ceiling value of $15 million and an ultimate completion date of March 26, 2025. This BPA, established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), enables the Department of Veterans Affairs to procure Jynarque (tolvaptan), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. The...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Advanced Accelerator Applications USA Inc., a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $23.4 million single-award BPA is under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of February 3, 2025. The BPA is for the procurement of LOCAMETZ and NETSPOT, two...

This Blanket Purchase Agreement, awarded October 2, 2025, establishes a single-award indefinite delivery vehicle with Novartis Pharmaceuticals Corporation for the procurement of four specialized pharmaceutical products: KYMRIAH (tisagenlecleucel-a CAR-T cell therapy), FABHALTA (200 mg formulation), NETSPOT (Gallium-68 dotatate), and LOCAMETZ. The contract, valued at $61.1 million with a ceiling through October 1, 2026, is funded by the National Acquisition Center and operates under the...

This Blanket Purchase Agreement, awarded on October 4, 2024, to Takeda Pharmaceuticals America, Inc., establishes a single-award indefinite delivery vehicle valued at $123.5 million for the procurement of ICLUSIG (ponatinib), a specialized oncology pharmaceutical product. The contract is administered by the National Acquisition Center, a civilian federal agency, and will remain in effect through September 17, 2025. As a child contract under the parent General Services Administration Schedule for...

Incyte Corporation has been awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) National Acquisition Center for the supply of Pemazyre (pemigatinib), an oncology pharmaceutical indicated for the treatment of specific cancer types. The contract, valued at $7.87 million, was awarded on December 3, 2025, with an ultimate completion date of December 2, 2026. This BPA represents a renewal or continuation of the existing $3.75 million single-award...

This Blanket Purchase Agreement (BPA), awarded to BioMarin Pharmaceutical Inc. on October 15, 2021, establishes a framework for the supply of Palynziq (pegvaliase-pqpz) to the Veterans Affairs (VA) system through the GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract carries a ceiling value of $151,685 and extends through October 14, 2026, with performance conducted from BioMarin's location in Novato, California. The award was made as a single-award, non-set-aside procurement under...